Target | Inhibitors | Chemical Structure | Source | Products | IC50 (μM) | Solubility | Applicability (Cells) | Activity | Assay | Study |
---|---|---|---|---|---|---|---|---|---|---|
SENP1 | Triptolide | Extracted from the Chinese herb Tripterygium wilfordii Hook F | Natural | 0.0203 | DMSO | LNCaP, PC-3 | In vivo and in vitro | From the Chinese herb | Huang et al. (2012) | |
Compound J5 | 2-(4-Chlorophenyl)-2-oxoethyl 4-benzamidobenzoate derivatives | Synthetic | 2.385 | DMSO | — | In vitro | Virtual screening and docking | Chen et al. (2012b) | ||
Compound 4 | 1-[4-(N-benzylamino) phenyl]-3-phenylurea derivatives | Synthetic | 29.6 | — | HeLa | In vitro | In silico screening | Uno et al. (2012) | ||
Compound 13m | 4ʹ-Methoxy-biphenyl-3-carboxylic acid 3(3-phenylpropionylamino)-benzylamide | Synthetic | 3.5 | DMSO | — | In vitro | In silico screening and rational drug design | Zhao et al. (2016) | ||
Momordin Ic (Mc) | A pentacyclic triterpenic compound | Natural | 15.37 | DMSO | PC-3 | In vivo and in vitro | Cellular thermal shift assay | Wu et al. (2016) | ||
Compound 3 | Based on hydrolysis of RanGAP-SUMO | Synthetic | 3.3 | — | — | In vitro | A quantitative assay based on readily available SDS-PAGE–Coomassie system | Xie et al. (2016) | ||
SENP2 | Compound 69 | A class of 1,2,5-oxadiazoles | Synthetic | 5.9 | DMSO | — | In vitro | Combination of structure based virtual screening and quantitative FRET-based assay. | Kumar et al. (2014) | |
Compound 117 | Synthetic | 3.7 | DMSO | — | In vitro | |||||
Ebselen | 2-phenyl-1,2-benzoselenazol-3-one | Synthetic | 2 | DMSO | B35 | In vivo and In vitro | A quantitative high-throughput screen | Bernstock et al. (2018b) |
—, No relevant information found in the literature; CDH1, cadherin-1; CDK, cyclin-dependent kinase; H2AX, H2A histone family member X; HIF-1, hypoxia-inducible factor 1; MMP, matrix metalloproteinase; NF-κB, nuclear factor κB; PDAC, pancreatic ductal adenocarcinoma cells; ROS, reactive oxygen species; TGFβ, transforming growth factor β; TNM, tumor, node, and metastases staging system.